Ultima Genomics to provide low-cost $100 genome sequencing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ultima Genomics is developing a high-throughput, low-cost sequencing platform that delivers $100 genome sequencing. Ultima has secured approximately $600 million in backing.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The definition of “therapeutic imperative” is this: A treatment necessity that must be met in order to prevent death. Once the imperative is clearly defined, addressing it properly links correct diagnosis with therapy and favorable prognosis. On the other hand, misdiagnosis or inadequate diagnosis fails to provide a framework for highly effective or curative therapy. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login